FDA Approves LUMVOA — Viridian Therapeutics, Inc.

Viridian Therapeutics announced Tuesday that FDA approval of its intravenous therapy Veligrotug (brand name Lumvoa) has been granted, marking a significant milestone that positions the product to leverage its specific pharmacokinetic profile. The authorization unlocks substantial market potential by targeting a critical patient population with an established IV delivery route, paving the way for immediate commercial release and substantial revenue generation upon launch.